Sector Gamma AS Acquires 30,980 Shares of Edwards Lifesciences Corporation $EW

Sector Gamma AS raised its stake in Edwards Lifesciences Corporation (NYSE:EW) by 73.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 72,980 shares of the medical research company’s stock after purchasing an additional 30,980 shares during the quarter. Edwards Lifesciences accounts for about 1.4% of Sector Gamma AS’s portfolio, making the stock its 28th biggest position. Sector Gamma AS’s holdings in Edwards Lifesciences were worth $5,676,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Norges Bank bought a new position in Edwards Lifesciences during the 2nd quarter valued at $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in shares of Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after purchasing an additional 4,805,819 shares during the last quarter. Marshall Wace LLP lifted its position in shares of Edwards Lifesciences by 127.5% during the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after purchasing an additional 3,864,908 shares in the last quarter. Jennison Associates LLC boosted its holdings in Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after purchasing an additional 2,287,783 shares during the last quarter. Finally, Holocene Advisors LP grew its position in Edwards Lifesciences by 35.2% in the 2nd quarter. Holocene Advisors LP now owns 4,703,977 shares of the medical research company’s stock worth $367,898,000 after purchasing an additional 1,223,460 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the sale, the vice president owned 31,870 shares in the company, valued at approximately $2,729,984.20. This trade represents a 26.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This represents a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 57,824 shares of company stock worth $4,863,323 in the last three months. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $83.70 on Friday. The business’s fifty day moving average is $84.99 and its 200 day moving average is $80.83. The firm has a market cap of $48.57 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 3.19 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the firm earned $0.67 EPS. The company’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on EW shares. UBS Group reiterated a “neutral” rating and issued a $95.00 price objective (up previously from $92.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. National Bankshares set a $92.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 31st. Evercore ISI reissued an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 5th. Jefferies Financial Group set a $98.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, BTIG Research reaffirmed a “buy” rating and set a $103.00 price target (up previously from $100.00) on shares of Edwards Lifesciences in a research report on Thursday, December 4th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $96.82.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.